RemeGen Co. Ltd. Class A
688331
Clasificación en acciones
#2412
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Precio por acción
$14.49
Capitalización bursátil
$8.11B
Cambio (1 día)
2.99%
Cambio (1 año)
9.18%
País
CN
Comercio RemeGen Co. Ltd. Class A (688331)
Categoría
Healthcare
Ganancias de RemeGen Co. Ltd. Class A (688331)
Ganancias en Jun 2026 TTM: $843.65M
Secondo gli ultimi rapporti finanziari di RemeGen Co. Ltd. Class A, gli utili attuali della società sono $843.65M. Nel 2023, la società ha registrato un utile di $-213.49M, una disminución en comparación con agli utili del 2022, che erano di $-144.80M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de RemeGen Co. Ltd. Class A desde 2018 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $843.65M | -519.37% |
| 2024 | $-201.17M | -5.77% |
| 2023 | $-213.49M | 47.44% |
| 2022 | $-144.80M | -433.15% |
| 2021 | $43.46M | -140.69% |
| 2020 | $-106.82M | 72.87% |
| 2019 | $-61.79M | 57.45% |
| 2018 | $-39.24M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | 525.25% |
US
|
|
| $-3.09B | -465.91% |
US
|
|
| $-4.02B | -576.05% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 131.22% |
NL
|
